Hologic (HOLX) Projected to Post Earnings on Thursday

Hologic (NASDAQ:HOLX - Get Free Report) will likely be announcing its Q2 2025 earnings results after the market closes on Thursday, May 1st. Analysts expect Hologic to post earnings of $1.02 per share and revenue of $1.00 billion for the quarter. Hologic has set its Q2 2025 guidance at 1.000-1.030 EPS and its FY 2025 guidance at 4.250-4.350 EPS.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, analysts expect Hologic to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Hologic Price Performance

Hologic stock opened at $58.19 on Thursday. The firm's 50-day moving average is $61.24 and its two-hundred day moving average is $70.37. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The stock has a market capitalization of $13.06 billion, a P/E ratio of 18.36, a P/E/G ratio of 2.14 and a beta of 0.82. Hologic has a 12-month low of $55.89 and a 12-month high of $84.67.

Wall Street Analyst Weigh In

Several analysts have commented on HOLX shares. Stephens reaffirmed an "overweight" rating and issued a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. Royal Bank of Canada dropped their target price on Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a research note on Thursday, February 6th. Evercore ISI decreased their price target on Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a research note on Thursday, February 6th. Leerink Partnrs downgraded shares of Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Finally, Needham & Company LLC cut shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 target price on the stock. in a research report on Monday, February 3rd. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.